PRMT5 and breast carcinoma: In this study, genetic and pharmacological inhibition of the methyltransferase activity of PRMT5 in ER+/RB-deficient human breast cancer cells blocked the G1-to-S cell cycle transition and arrested their proliferation despite loss of RB – the canonical mechanism regulating arrest of cells in G1 phase of the cell cycle.